A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.
Peter Benko, PharmD Candidate Class of 2021, the University of Connecticut
Advertisement
Articles by Peter Benko, PharmD Candidate Class of 2021, the University of Connecticut
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5